ライフサイエンスコーパス: retroviral

1 prove useful in exploring genes important in retroviral activation and ALS, which may help discover n

2 o support pathological links between ALS and retroviral activation.

3 essed, the P. maniculatus TRIMCyp shows anti-retroviral activity that is reversed by cyclosporine, bu

4 cturally distinct immature capsid is a later retroviral adaptation, while the structure of mature ass

5 Human immunodeficiency virus 1 (HIV-1), the retroviral agent of acquired immune deficiency syndrome,

6 Over 50 000 experimental records for anti-retroviral agents from ChEMBL database were extracted fo

7 In mouse models of retroviral AML transplantation, as well as in retrospect

8 uce mutational signatures in targets such as retroviral and cancer cell genomes.

9 t binding protein 1 (PTBP1) shields specific retroviral and cellular transcripts from NMD.

10 nome size, bats have comparable diversity of retroviral and non-retroviral endogenous sequences to ot

11 nown roles of tRNAs and their derivatives in retroviral and retrotransposon replication and shed ligh

12 ved, which enhances current knowledge of the retroviral assembly pathway.

13 ences will provide greater insights into the retroviral assembly pathway.

14 appaB activity, especially in the context of retroviral assembly.

15 By combining retroviral-based multicolor clonal analysis with live im

16 Likewise, Fgf2 -/- mice transplanted with retroviral BCR-ABL leukemia survive significantly longer

17 ally prolonged survival in a murine model of retroviral BCR-ABL-driven CML and impaired the in vivo s

18 A dynamics represent fundamental features of retroviral biology and whether they occur for other posi

19 A dual-virus tracing strategy combining retroviral birthdating with rabies virus-mediated putati

20 Gag is the only viral component required for retroviral budding from infected cells.

21 IX to function in cytokinetic abscission and retroviral budding, but not in multivesicular body sorti

22 a retrovirus with a host cell membrane, the retroviral capsid is released into the cytoplasm of the

23 pha binds to and forms assemblies around the retroviral capsid.

24 The structures of retroviral capsids have been extensively described.

25 alpha can induce the abortive disassembly of retroviral capsids have remained obscure, numerous studi

26 uses its rapidly evolving 'v1' loop to bind retroviral capsids, and single mutations in this loop ca

27 ssary to recognize divergent and pleomorphic retroviral capsids.

28 pha to accommodate the variable curvature of retroviral capsids.

29 CD169-mediated retroviral capture activated conventional dendritic cell

30 manent renewal of placenta-specific genes by retroviral capture and de facto provide a candidate gene

31 We provide evidence that the associated retroviral capture event most probably occurred >100 Mya

32 hain in combination with a second-generation retroviral CAR transduction including a 4-1BB costimulat

33 to silence urothelial RNase 7 production and retroviral constructs to stably overexpress RNase 7; we

34 ell that surrounds and protects the incoming retroviral core.

35 rm the unique polyhedral structures found in retroviral cores.

36 is inactive in isolation, in contrast to its retroviral counterpart.

37 Using a newly developed, genome-wide retroviral CRISPR knockout (KO) library, combined with R

38 -stranded RNA targets remains challenging as retroviral-derived reverse transcriptases are often not

39 nario suggests a role for cell-free virus in retroviral disease progression.

40 sgene in order to study how tetherin affects retroviral dissemination and on which cell types its exp

41 tion and direct cell-to-cell transmission to retroviral dissemination and pathogenesis are unknown.

42 Herein we review the molecular mechanism of retroviral DNA integration, with an emphasis on reaction

43 des new insight into the structural basis of retroviral DNA integration.

44 tein 16 (IFI16) is known as immune sensor of retroviral DNA intermediates.

45 eus of the host cell, linear double-stranded retroviral DNAs are either integrated into the host geno

46 The unintegrated retroviral DNAs are potently silenced, and we provide ev

47 chromatinization status of the unintegrated retroviral DNAs of the human immunodeficiency virus type

48 eal insights into the nature of unintegrated retroviral DNAs.

49 n given the anticancer drug gefitinib or the retroviral drug atazanavir, the Por-deleted humanized PI

50 Combination anti-retroviral drug therapy (ART) potently suppresses HIV-1

51 ingredients (APIs), such as antitumourals or retroviral drugs (with high loading and slow release tim

52 Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency v

53 ison exon that is derived from an endogenous retroviral element and subsequent degradation of BRD9 mR

54 Accordingly, a set of endogenous retroviral element RNAs were upregulated in metastatic c

55 r target for strategies aimed at attenuating retroviral element sensing, via MAVS, to treat dementia

56 , ZSCAN4, KDM4E and PRAMEF-family genes) and retroviral elements (MERVL/HERVL family) that define the

57 nscriptional activation of genes, endogenous retroviral elements and chimeric transcripts initiated f

58 have provided a causal link between genomic retroviral elements and cognitive decline; however, in m

59 Although many of these retroviral elements have lost their ability to replicate

60 lation and enhanced expression of endogenous retroviral elements in lymphoma cells.

61 , protocadherins, Rhox genes, and endogenous retroviral elements resulted in the upregulation of IFN

62 tory function in reporter assays, identified retroviral elements with activating roles, and uncovered

63 of our transcriptome derives from integrated retroviral elements, termed endogenous retroviruses (ERV

64 ctivate tumour cell expression of endogenous retroviral elements, thus increasing intracellular level

65 survey genes, as well as specific endogenous retroviral elements.

66 on, and may suggest evolutionary outcomes of retroviral endogenization.

67 e comparable diversity of retroviral and non-retroviral endogenous sequences to other mammals.

68 anscriptome and screened for the presence of retroviral env genes with a full-length ORF.

69 In this study, we identified a retroviral envelope gene capture and exaptation that too

70 ia and Euarchontoglires, with the identified retroviral envelope gene encoding a full-length protein

71 Capture of retroviral envelope genes from endogenous retroviruses h

72 Capture of retroviral envelope genes is likely to have played a rol

73 ntal transcripts and searched for endogenous retroviral envelope genes that have been captured specif

74 At variance with previously identified retroviral envelope genes, its encoding gene is found to

75 ammals, due in part to stochastic capture of retroviral envelope genes.

76 has been mapped to a conserved domain of the retroviral envelope glycoprotein of several exogenous as

77 chanism of immunosuppression mediated by the retroviral envelope glycoprotein.

78 These vesicles carried endogenous retroviral envelope protein syncytin 1 and essentially a

79 Retroviral envelopes are known to be capable of elicitin

80 proteins deriving from ancestral endogenous retroviral envelopes.

81 The retroviral enzyme integrase plays an essential role in t

82 IRT exhibits more slippage in vitro than the retroviral enzymes tested including that from HIV.

83 details of the structure and function of the retroviral enzymes-reverse transcriptase, protease, and

84 Spen loss activates a subset of endogenous retroviral (ERV) elements in mouse embryonic stem cells,

85 d TRIM28 leads to derepression of endogenous retroviral (ERV) elements, unmasking this cellular sourc

86 t the Sd mutation results from an endogenous retroviral (ERV) insertion upstream of the Ptf1a gene re

87 abited areas, the likelihood of new zoonotic retroviral exposures increases.

88 immortalization of myeloid progenitors using retroviral expression of an estrogen-dependent fusion pr

89 in complex II, all of which were rescued by retroviral expression of wild-type FOXRED1.

90 S2 shares no sequence homology with other retroviral factors known to counteract SERINC5.

91 s discovery closes the last major gap in the retroviral fossil record and provides important insights

92 These data provide insight into retroviral frameshifting and could lead to alternative s

93 al trophoblasts via expression of endogenous retroviral fusogens known as syncytins forms the syncyti

94 n lattice on the host's plasma membrane, the retroviral Gag polyprotein triggers formation of the vir

95 Retroviral Gag polyproteins are targeted to the inner le

96 Retroviral Gag polyproteins orchestrate the assembly and

97 The capsid domain (CA) of the retroviral Gag protein is a primary determinant of Gag o

98 consistent with a role for the MA domain of retroviral Gag proteins in modulating nucleic acid bindi

99 ogenesis, delineated mechanisms that control retroviral gene expression, and elucidated critical deta

100 crucial factor in leukemogenic potential of retroviral gene therapy and underscore the importance of

101 Retroviral gene therapy has proved efficacious for multi

102 ion of therapeutic transgene expression from retroviral gene therapy vectors by epigenetic defence me

103 Previous attempts using retroviral gene transfer to correct murine CD40L express

104 y believed that intasomes derived from other retroviral genera use tetrameric integrase.

105 roviral vectors derived from three different retroviral genera.

106 ong representative retroviruses in the known retroviral genera.

107 ent protein) created from all representative retroviral genera: Alpharetrovirus, Betaretrovirus, Delt

108 Overall, our findings provide evidence that retroviral genes contribute to tumoral immunosurveillanc

109 By reconstructing the canonical retroviral genes, we identified patterns of adaptation c

110 on of HIV-1 is highly constrained, since the retroviral genome must contain a slippery sequence (sequ

111 ion of murine leukemia virus genomes but not retroviral genomes of the lentiviral or betaretroviral f

112 MT generated 100-fold more beating iCMs than retroviral-GMT and shortened the duration to induce beat

113 transfer of SeV-GMT was more efficient than retroviral-GMT in reprogramming resident cardiac fibrobl

114 es and by motif searches in Human Endogenous Retroviral (HERV) RNA sequences.

115 In summary, our results indicate that retroviral host range extension is caused by spontaneous

116 offers the opportunity to induce protective retroviral immunity by restoration of retrovirus-specifi

117 BP-associated factor plays a central role in retroviral infection and cancer development, and the C-t

118 ugh the susceptibility of murine EC cells to retroviral infection has been extensively analyzed, few

119 n antiviral restriction factor that inhibits retroviral infection in a species-specific fashion.

120 amined the ability of TRIM5alpha to restrict retroviral infection in cells depleted of the autophagic

121 Retroviral infection involves the reverse transcription

122 e requirements for control or elimination of retroviral infection remains an important aim.

123 roles of +TIPs in mediating early stages of retroviral infection, and reveal divergent capsid-based

124 esent a new therapeutic avenue to fight this retroviral infection, as it reestablishes the Th1/Th2 ba

125 domain proteins that have been implicated in retroviral infection, inflammation pathways, and cancer

126 semble the proviruses created from exogenous retroviral infection.

127 tors that may hold promise as treatments for retroviral infections and neurodegenerative disease.

128 proteins are restriction factors that block retroviral infections by binding viral capsids and preve

129 ogenous retroviruses (ERVs), the remnants of retroviral infections in the germ line, occupy ~8% and ~

130 mmune system, including ISGs, in controlling retroviral infections is currently an area of intensive

131 ay a beneficial role in mitigating exogenous retroviral infections.

132 us retroviruses (ERVs), derived from ancient retroviral infections.

133 y labeled new granule cells at 7-8 days post retroviral injection (dpi) show that these cells respond

134 concerted strand transfer activity of delta-retroviral INs in vitro.

135 acute myeloid leukemias (AMLs) generated by retroviral insertional mutagenesis in Kras(G12D) "knocki

136 Yet, retroviral insertional mutagenesis screens identify RUNX

137 Here, we recruited retroviral insertional mutagenesis to obtain induction o

138 ed primitive genetic characters, we analysed retroviral insertions in 80 modern Kihnu sheep and 83 an

139 d that endogenous avian leukosis virus (ALV) retroviral insertions were not mobilized during in vitro

140 tures highlight how HIV-1 can use the common retroviral intasome core architecture to accommodate dif

141 termine that the prototype foamy virus (PFV) retroviral intasome searches for an integration site by

142 erial into the host genome, catalysed by the retroviral integrase (IN) enzyme.

143 Retroviral integrase (IN) functions within the intasome

144 dal interaction with chromatin and the gamma-retroviral integrase (IN).

145 Retroviral integrase can efficiently utilise nucleosomes

146 Retroviral integrase catalyses the integration of viral

147 Retroviral integrase forms a higher order nucleoprotein

148 or viral replication and is catalyzed by the retroviral integrase.

149 new questions about the role of histones in retroviral integration and transcription.

150 Here, we develop a biophysical model for retroviral integration as stochastic and quasi-equilibri

151 Herein, I review the mechanisms of retroviral integration as well as the promises and chall

152 Thus, retroviral integration into nucleosomes involves the loo

153 The location of retroviral integration into the human genome is thought

154 Retroviral integration proceeds via two integrase activi

155 usly unappreciated physical contributions to retroviral integration site selection.

156 these mutations occur in the same intron as retroviral integration sites in gene therapy-induced T-A

157 BET proteins guide gamma-retroviral integration to transcription start sites and

158 ially informing future strategies to prevent retroviral integration.

159 nd suggest that target site-selection limits retroviral integration.

160 INSTIs work by blocking retroviral integration; an essential step in the viral l

161 rtical transfer, allowing direct analysis of retroviral invasion of the germline genome.

162 ovo piRNA birth as host responds to a recent retroviral invasion.

163 gh lineage tracking through the injection of retroviral libraries has long been the state of the art,

164 Integration is a key feature of the retroviral life cycle.

165 interactions that promote late steps of the retroviral life cycle.

166 ons of adenosine to inosine modifications in retroviral life cycles.

167 that mutations in ASPRV1 (aspartic peptidase retroviral-like 1) cause a dominant Mendelian disorder f

168 l domain (helical domain of Ddi1, HDD) and a retroviral-like protease (RVP) domain.

169 hylogenetic analyses suggest that this major retroviral lineage, and therefore retroviruses as a whol

170 sposable elements (TE), including endogenous retroviral long terminal repeats (LTR), short and long i

171 Using an unbiased retroviral loss-of-function screen in nontransformed hum

172 a unique CpG-rich promoter not related to a retroviral LTR, with sites of expression including the p

173 s to characterize the interactions anchoring retroviral MA at the plasma membrane of infected cell.

174 ct shRNA (cshRNA) expression system based on retroviral microRNA (miRNA) gene architecture that uses

175 -2 Spike glycoprotein (SPG) on a traditional retroviral (MMLV) as well as a third generation lentivir

176 d we confirmed our results in a Friend virus retroviral model of infection in mice.

177 9), which is fully transforming in a murine retroviral model, in human cord blood cells.

178 Using a well-established retroviral model-avian Rous sarcoma virus (RSV)-we analy

179 ma membrane targeting differs among distinct retroviral morphogenetic types.

180 In a retroviral mouse model performed in Mpl(-/-) mice, MPL P

181 mRNA, and it also is essential for export of retroviral mRNAs with retained introns.

182 Using transfected (retroviral oncogene or fluorescent reporter construct) r

183 ade substantial contributions in the area of retroviral oncogenesis, delineated mechanisms that contr

184 py using stem cells or T cells transduced by retroviral or lentiviral vectors has shown remarkable ef

185 Approximately 8% of the human genome is of retroviral origin.

186 Retroviral overexpression of Cdx2 induces AML in mice, h

187 Retroviral overexpression of SOCS3 in HepG2 cells (HepG2

188 capsid core structure.IMPORTANCE Studies of retroviral particle core morphology have demonstrated a

189 Retroviral particles assemble on the PM and bud from inf

190 The assembly of immature retroviral particles is initiated in the cytoplasm by th

191 IV-1 infection and cancer, HK2 genes produce retroviral particles that appear to be infectious, yet t

192 mmune system is an effective defense against retroviral pathogenesis, resulting in reduced viral repl

193 ransmission or control pathogenesis of human retroviral pathogens.

194 cell line presented AH1, a common endogenous retroviral peptide.

195 y pacidamycin moiety with the synthetic anti-retrovirals, presents a potential opportunity for the ut

196 This study highlights the malleability of retroviral protease folding pathways by illustrating how

197 ontain a conserved region with similarity to retroviral proteases, but whether and how DDI2 functions

198 ns (MAs) play a key role in the transport of retroviral proteins inside infected cells and in the int

199 This inhibition is counteracted by retroviral proteins, specifically, HIV-1 Nef, MLV glycoG

200 icken embryos, we used replication-competent retroviral RCAS vector system to generate transgenic chi

201 has suggested that xenotropic and polytropic retroviral receptor 1 (XPR1) might be involved in this p

202 n defect in patient T cells were restored by retroviral reconstitution.

203 important in enhancing our understanding of retroviral replication and pathogenesis, including that

204 Moreover, host cellular proteins regulate retroviral replication by binding to tRNAs and thereby a

205 leamine 2,3-dioxygenase 1 (IDO1) can inhibit retroviral replication by metabolite depletion while tri

206 cART is effective in stopping the retroviral replication cycle, but not in inhibiting clon

207 ependent dNTP depletion is thought to impair retroviral replication in these cells, but the relations

208 he two domains to face each other.IMPORTANCE Retroviral replication requires that some of the viral R

209 ential molecules of life range from roles in retroviral replication to stimulation of mammalian targe

210 Here, we show that cells survive retroviral replication, both in vitro and in vivo in SIV

211 whereas in non-cycling cells restrictive to retroviral replication, SAMHD1 activation is likely to b

212 e innate immune system substantially reduced retroviral replication, set point, and pathogenesis.IMPO

213 l proteins and RNAs and potentially regulate retroviral replication.

214 into host chromatin is the defining step of retroviral replication.

215 s to interferon signaling and restriction of retroviral replication.

216 ctrophysiological recordings and fluorescent retroviral reporter birthdating.

217 e role of specific ubiquitin linkages in the retroviral restriction and autophagic degradation of TRI

218 s that the inhibition of autophagy abrogates retroviral restriction by TRIM5 proteins.

219 e for K63-linked ubiquitin in the process of retroviral restriction by TRIM5alpha and potentially pro

220 tetramerization is not likely to explain the retroviral restriction defect, and we hypothesize that e

221 One of these genes, TRIM5, is a retroviral restriction factor that mediates a post-entry

222 TRIM5alpha is an interferon-inducible retroviral restriction factor that prevents infection by

223 SAMHD1 functions as an important retroviral restriction factor through a mechanism relyin

224 cannot rule out a contribution of SAMHD1 to retroviral restriction in relatively non-permissive CNS

225 The contributions of SAMHD1 to retroviral restriction in the central nervous system (CN

226 elationship between the dNTPase activity and retroviral restriction is not fully understood.

227 SAMHD1-mediated retroviral restriction is thought to result from the dep

228 ations in this loop can dramatically improve retroviral restriction.

229 Retroviral reverse transcriptase (RT) of Moloney murine

230 ed nucleotide sequences derived from the non-retroviral RNA bornavirus.

231 el cofactor for ZAP to target CpG-containing retroviral RNA for degradation.

232 protein essential for XCI , binds to ancient retroviral RNA, performing a surveillance role to recrui

233 ecessors of retrotransposon, telomerase, and retroviral RTs as well as the spliceosomal protein Prp8

234 active site are surprisingly different from retroviral RTs but remarkably similar to viral RNA-depen

235 and other non-LTR retroelements differ from retroviral RTs in being able to template-switch efficien

236 Retroviral (RV) expression of genes of interest (GOIs) i

237 ntains thousands of loci composed of ancient retroviral sequences known as endogenous retroviruses (E

238 Endogenous retroviral sequences provide a molecular fossil record o

239 These include Class I and Class II retroviral sequences, foamy viruses, and deltaretrovirus

240 chromatin remodeling at specific endogenous retroviral sequences.

241 Using retroviral shRNA knockdown, we have demonstrated that th

242 between two repressive pathways involved in retroviral silencing in mammalian cells.

243 Like other retroviral species, the Gag polyprotein of HIV-1 contain

244 the CA-NC connecting region differs between retroviral species.

245 al divergent capsid-based EB1 mimicry across retroviral species.

246 The retroviral structural protein Gag binds to the inner lea

247 Binding of the retroviral structural protein Gag to the cellular plasma

248 Our findings underscore the importance of retroviral structural proteins for integration site sele

249 Here, we studied retroviral susceptibility in a transgenic mouse model wi

250 of EIAV as a determinant that also modulates retroviral susceptibility to SERINC5, indicating that EI

251 tasomal core, previously observed in simpler retroviral systems, is formed between two IN tetramers,

252 as important as selection for resistance in retroviral systems.

253 It is a known hot spot of retroviral tagging insertion and a fusion partner of bot

254 IV-infected individuals off combination anti-retroviral therapy (14 with HAND) who underwent detailed

255 Combination anti-retroviral therapy (ART) has revolutionized the treatmen

256 Anti-Retroviral Therapy (ART) is the recommended first line t

257 subjects and those either treated with anti-retroviral therapy (ART) or untreated.

258 Combination anti-retroviral therapy (cART) has drastically improved the c

259 ction, and remains elevated in those on anti-retroviral therapy (cART).

260 e dysfunction, and the effects of early anti-retroviral therapy administration.

261 The advent of effective retroviral therapy and use of rituximab in HHV8-MCD have

262 SHIV infection differs from combination anti-retroviral therapy in that it facilitates the emergence

263 to therapy and can be reactivated upon anti-retroviral therapy interruption.

264 ration should be taken when choosing an anti-retroviral therapy regimen.

265 of new anti-tuberculars compatible with anti-retroviral therapy we re-identified amicetin as a lead c

266 s treated for 15 weeks with combination anti-retroviral therapy, beginning on day 3 after infection,

267 ich can then be eliminated by effective anti-retroviral therapy.

268 The methods have been validated against retroviral tracer studies.

269 RNA sequencing detected endogenous retroviral transcripts.

270 After retroviral transduction in human peripheral blood NK cel

271 Retroviral transduction is routinely used to generate ce

272 Targeted deletion of Pbx1 by retroviral transduction of Cre recombinase into Pbx2-def

273 TCF7 retroviral transduction opposes GZMB expression and the

274 in a luciferase reporter assay and following retroviral transduction.

275 of HLA-A*02:01-positive DeltaNPM1 AML after retroviral transfer to CD8+ and CD4+ T cells.

276 chanisms of CA decomposition/degradation and retroviral uncoating, which may lead to new approach for

277 fied with the human ADA cDNA (MND-ADA) gamma-retroviral vector after conditioning with busulfan (90 m

278 at contained CD34(+) cells transduced with a retroviral vector encoding the human ADA complementary D

279 NK cells were transduced with a retroviral vector expressing genes that encode anti-CD19

280 mpts at gene therapy for WAS using a Upsilon-retroviral vector improved immunological parameters subs

281 analyze next-generation sequencing data for retroviral vector integration sites.

282 Here we used a retroviral vector to express an oncogene specifically in

283 ogous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30

284 R) alpha- and beta-chains were cloned into a retroviral vector.

285 ibility of human EC cells to transduction by retroviral vectors derived from three different retrovir

286 Following co-transduction of three or four retroviral vectors encoding individual cardiogenic trans

287 uced bronchial epithelial BEAS-2B cells with retroviral vectors expressing KRAS(G12V) and monitored m

288 studies, autologous gene therapy with gamma-retroviral vectors failed to reconstitute B-cell and NK-

289 tment of AIDS and the utility of integrating retroviral vectors in gene therapy applications.

290 also carried out for cell lines generated by retroviral vectors in in vitro studies.

291 Transgenes were overexpressed from retroviral vectors in primary human keratinocytes.

292 refore, the analysis of integration sites of retroviral vectors is a crucial step in developing safer

293 ed into the T cells of a patient using gamma-retroviral vectors or other randomly integrating vectors

294 nces the infectivity of lentiviral and gamma-retroviral vectors pseudotyped with various envelope gly

295 We used retroviral vectors to express PML-RARA, RUNX1-RUNX1T1, o

296 The initial gamma-retroviral vectors, next-generation lentiviral vectors,

297 nts using transgenes expression in EPCs from retroviral vectors.

298 pecially SERINC5, inhibit the infectivity of retroviral virions.

299 cessory protein from EIAV is an example of a retroviral virulence determinant that independently evol

300 viral elements (EVEs) are sequences from non-retroviral viruses that are inserted into the mosquito g